宜宾哪家医院彩光嫩肤好(宜宾伊婉玻尿酸怎么样) (今日更新中)

WEST PALM BEACH, Fla. — The hurricane season continues to be active with the formation of a new tropical storm and a depression in the last 12 hours.Tropical depression 17 formed Sunday night in the Atlantic and became Tropical Storm Paulette just before 11 a.m. Monday.The storm has 40 mph winds with higher gusts and is moving west, northwest at 3 mph.Paulette is the earliest forming 16th named storm on record, breaking an old record set by Philippe on September 17, 2005, according to hurricane expert Philip Klotzbach.A slow-motion toward the northwest or north-northwest is expected tonight. Paulette is then forecast to move a little faster and generally westward on Tuesday and Wednesday.Early indications are it may curve before it reaches the Bahamas, but we will keep an eye on it just in case. It may interact with tropical depression 18, located behind it, which also formed Monday morning.Paulette's path and/or intensity might change because of its proximity to tropical depression 18. 1009

With five months to go until the November election, a unique group of voters could play a pivotal rule in deciding the next president: felons. THE ISSUEA Florida judge recently ruled felons, who have left prison, should not be required to pay fines before they are allowed to vote. Last year, Florida's governor signed a law making it a requirement to vote again. The judge referred to it as a “pay-to-vote system."Florida's governor is appealing the ruling. The issue of what voting rights felons have varies across the country and depends on where the felon resides. Some states, like Maine, allow felons to vote while incarcerated. In the majority of states, felons are automatically allowed to vote after they leave prison. In Iowa, felons aren't allowed to vote at all. Meanwhile in Virginia, their constitution bans felons from voting, but the governor has been using his authority to allow nonviolent felons to vote if they fill out a form.IMPACT ON ELECTIONIt's estimated there are around 1 million potential Florida voters impacted by the legal ruling. Given Florida's swing state status, that is a lot of new voters potentially up for grabs. Florida has 29 electoral college votes. President Donald Trump beat Hillary Clinton by just 112,000 votes in 2016. While the ruling is being appealed, it's unclear if it will be taken up by the Supreme Court before November's election. "I think there is certainly a movement to give people second chances, to let them rejoin the electorate," Julie Ebenstein, an ACLU lawyer who helped argue the case, said. Ebenstein believes this could impact other states in encouraging legal challenges. While Democratic leaders, for the most part, have taken steps to allow more felons to vote in recent years, it is unclear if it helps their party when it comes to elections. A Vox study found felons participate in elections at low rates and traditionally do not favor one party or another in large numbers. FELONS REACT"It's about 50-50 down the line inside," said Barbara Barrick, a Virginia felon, about the political affiliation of those who have served time. Barrick is following the Florida case because she believes felons should be treated equally regardless of the state in which they live. Barrick received her voting rights back in 2018 after the governor of Virginia issued a special order. "When I voted for the first time last November, I felt so real. I put my little sticker on. I was prancing around. I actually cried," Barrick said. 2501

William "Bill" Barr, a former attorney general under President George H.W. Bush, is emerging as a consensus candidate to succeed Jeff Sessions as attorney general, two sources familiar with President Donald Trump's thinking tell CNN.A third source familiar with the process said if Trump offered the position to Barr, he would be willing to accept.Trump's consideration of a new attorney general comes during a critical time for special counsel Robert Mueller's investigation, of which the next Justice Department chief will inherit oversight. Barr, 68, has previously offered mixed opinions about the investigation, having praised Mueller but also publicly criticizing political donations made by several members of his team.The Washington Post first reported that Barr is the leading candidate. Sources cautioned to CNN, however, that Trump makes the final decision.Barr served as Mueller's boss when he was attorney general in the early 1990s and Mueller led the criminal division at the Justice Department.The former attorney general hasn't shied away from weighing in on Mueller's investigation. He expressed confidence in Mueller early on and suggested the investigation wouldn't devolve into a "witch hunt," but he also has shared some disappointment when asked by The Washington Post last year about the donations that some of Mueller's team members made to Democrats."In my view, prosecutors who make political contributions are identifying fairly strongly with a political party ... I would have liked to see him have more balance on this group," he said in July 2017.Barr also defended Trump's decision to fire former FBI Director James Comey, who was criticized for flouting Justice Department protocols when he announced in July 2016 that he wouldn't recommend charges against Hillary Clinton for mishandling classified info during her time as secretary of state."I think it is quite understandable that the administration would not want an FBI director who did not recognize established limits on his powers," Barr wrote in a Washington Post op-ed in May 2017. "It is telling that none of the president's critics are challenging the decision on the merits."The prospect of Barr taking over the Justice Department was well-received by some leading members of Congress in both parties Thursday.Senate Majority Whip John Cornyn, a Texas Republican who sits on the Judiciary Committee, called Barr an "interesting pick.""I think getting the next nominee confirmed is going to be a little bit of a challenge," he said. "(Barr) may be the kind of person who would be easier to confirm."Sen. Dianne Feinstein, the top Democrat on the Judiciary Committee, said she was unfamiliar with Barr's views but encouraged by a suggestion that he was an "establishment" Republican."I would hope (Trump) would pick someone who would be by the book and not by the politics," Feinstein said.CNN reported late last month that Barr was among several potential candidates to succeed Sessions.At the time, CNN reported that Trump was considering tapping the assistant attorney general for the Justice Department's Antitrust Division, Makan Delrahim, to succeed acting Attorney General Matthew Whitaker. At the time, White House officials said Trump was in no rush to nominate a permanent successor to Sessions, whom he fired November 7. Instead, Trump was telling confidantes he was happy to leave Whitaker in place while he mulled his choices.Other names that have been floated as possible replacements for Sessions include Rep. John Ratcliffe of Texas, a former federal prosecutor, as well John Michael Luttig, a former US Court of Appeals judge, Justice Department official and current general counsel at Boeing. One former White House official said late last month that Luttig was a strong possibility, though he had not met with the President. A second source close to Luttig told CNN he was considered for the role of FBI director after Comey was fired in spring 2017.The-CNN-Wire 3983

With a coronavirus vaccine still months off, companies are rushing to test what may be the next best thing: drugs that deliver antibodies to fight the virus right away, without having to train the immune system to make them.Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help it be eliminated. Vaccines work by tricking the body into thinking there’s an infection so it makes antibodies and remembers how to do that if the real bug turns up.But it can take a month or two after vaccination or infection for the most effective antibodies to form. The experimental drugs shortcut that process by giving concentrated versions of specific ones that worked best against the coronavirus in lab and animal tests.“A vaccine takes time to work, to force the development of antibodies. But when you give an antibody, you get immediate protection,” said University of North Carolina virologist Dr. Myron Cohen. “If we can generate them in large concentrations, in big vats in an antibody factory ... we can kind of bypass the immune system.”These drugs are believed to last for a month or more and could give quick, temporary immunity to people at high risk of infection, such as health workers and housemates of someone with COVID-19. If they proved effective and if a vaccine doesn’t materialize or protect as hoped, the drugs might eventually be considered for wider use, perhaps for teachers or other groups.They’re also being tested as treatments, to help the immune system and prevent severe symptoms or death.“The hope there is to target people who are in the first week of their illness and that we can treat them with the antibody and prevent them from getting sick,” said Dr. Marshall Lyon, an infectious disease specialist helping to test one such drug at Emory University in Atlanta.Having such a tool “would be a really momentous thing in our fight against COVID,” Cohen said.Vaccines are seen as a key to controlling the virus, which has been confirmed to have infected more than 20 million people worldwide and killed more than 738,000. Several companies are racing to develop vaccines, but the results of the large final tests needed to evaluate them are months away.The antibody drugs are “very promising” and, in contrast, could be available “fairly soon,” said Dr. Janet Woodcock, a U.S. Food and Drug Administration official who is leading government efforts to speed COVID-19 therapies. Key studies are underway and some answers should come by early fall.One company, Eli Lilly, has already started manufacturing its antibody drug, betting that studies now underway will give positive results.“Our goal is to get something out as soon as possible” and to have hundreds of thousands of doses ready by fall, said Lilly’s chief scientific officer, Dr. Daniel Skovronsky.Another company that developed an antibody drug cocktail against Ebola — Regeneron Pharmaceuticals Inc. — now is testing one for coronavirus.“The success with our Ebola program gives us some confidence that we can potentially do this again,” said Christos Kyratsous, a Regeneron microbiologist who helped lead that work.Regeneron’s drug uses two antibodies to enhance chances the drug will work even if the virus evolves to evade action by one.Lilly is testing two different, single-antibody drugs — one with the Canadian company AbCellera and another with a Chinese company, Junshi Biosciences. In July, Junshi said no safety concerns emerged in 40 healthy people who tried it and that larger studies were getting underway.Others working on antibody drugs include Amgen and Adaptive Biotechnologies. The Singapore biotech company Tychan Pte Ltd. also is testing an antibody drug and has similar products in development for Zika virus and yellow fever.“I’m cautiously optimistic” about the drugs, said the nation’s top infectious diseases expert, Dr. Anthony Fauci. “I’m heartened by the experience that we had with Ebola,” where the drugs proved effective.What could go wrong?— The antibodies may not reach all of the places in the body where they need to act, such as deep in the lungs. All the antibody drugs are given through an IV and must make their way through the bloodstream to wherever they’re needed.— The virus might mutate to avoid the antibody — the reason Regeneron is testing a two-antibody combo that binds to the virus in different places to help prevent its escape.Skovronsky said Lilly stuck with one antibody because manufacturing capacity would essentially be cut in half to make two, and “you will have less doses available.” If a single antibody works, “we can treat twice as many people,” he said.— The antibodies might not last long enough. If they fade within a month, it’s still OK for treatment since COVID-19 illness usually resolves in that time. But for prevention, it may not be practical to give infusions more often than every month or two.A San Francisco company, Vir Biotechnology Inc., says it has engineered antibodies to last longer than they usually do to avoid this problem. GlaxoSmithKline has invested 0 million in Vir to test them.Giving a higher dose also may help. If half of antibodies disappear after a month, “if you give twice as much, you will have two months’ protection,” Lilly’s Skovronsky said.— The big fear: Antibodies may do the opposite of what’s hoped and actually enhance the virus’s ability to get into cells or stimulate the immune system in a way that makes people sicker. It’s a theoretical concern that hasn’t been seen in testing so far, but large, definitive experiments are needed to prove safety.“As best as we can tell, the antibodies are helpful,” Lyon said.___Marilynn Marchione can be followed on Twitter: @MMarchioneAP___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 5919

WICHITA FALLS, Texas — A man who was in jail awaiting trial for charges of sexually assaulting a child was released after his parents won the lottery and he posted a 0,000 bond.Jason Carlile is the 47-year-old suspect's name, and he is out from behind bars with an ankle bracelet for monitoring by authorities as well as a curfew. Carlile is the same man who was convicted in 2007 of buying a 15-year-old girl from the girl's mother. He served a three-year sentence.The girl's mother was also given a prison sentence in the incident, KFDX reports.Carlile's mother and stepdad won million in the Oct. 31 Lotto Texas drawing. It was purchased at a Fill and Chill store.The Times Record News reports Carlile has a history of sex crimes involving children.In 1994, there was an arrest warrant for him for exposing the genitals of another adult to a child and recording it.  914

来源：资阳报